The advent of immune checkpoint inhibitors (ICIs) has transformed the treatment landscape of various malignancies. While these therapies have demonstrated significant efficacy, they are often accompanied by immune-related adverse events (irAEs). Among these, h... ...

请注册登录后继续浏览